Regaal Resources Reports Strong FY26 Financials and Expansion

Regaal Resources Limited has announced its audited standalone financial results for the fiscal year ending March 31, 2026. The company reported a significant 23.9% year-on-year increase in operating income, reaching ₹1,134.2 crore. Profit After Tax (PAT) also saw a healthy rise of 16.6% to ₹55.6 crore.

Operational Growth and Strategy

Alongside its financial performance, Regaal Resources provided an update on its operational expansion. The company has doubled its maize crushing capacity to 1,650 metric tons per day. This expansion is a key part of its strategy to handle larger volumes and achieve better economies of scale.

The company is also strategically shifting towards higher value-added specialty maize products, including Liquid Glucose and Maltodextrin. This move aims to improve long-term profitability and product differentiation.

Future Expansion Plans

Regaal Resources is further enhancing its specialty product offerings with ongoing expansions planned for FY27. These include facilities for modified starch products, Dextrose Anhydrous, Dextrose Monohydrate, and Hydrol. The company's ultimate goal is to transform into a diversified maize-based specialty products company.

Margin Considerations

While revenue and absolute profits have grown, a slight compression in operating margins was observed. The Operating EBITDA margin decreased to 11.2% in FY26 from 12.3% in FY25, and the PAT margin also dipped from 5.2% to 4.9%. Investors will be watching to see if increased scale and new product lines can improve margins in the coming quarters.

Key Financials and Metrics (FY26):

• Operating Income: ₹1,134.2 crore (up 23.9% YoY)
• Profit After Tax (PAT): ₹55.6 crore (up 16.6% YoY)
• Diluted EPS: ₹5.81 (down 3.6% YoY)
• Operating EBITDA Margin: 11.2% (vs. 12.3% in FY25)
• PAT Margin: 4.9% (vs. 5.2% in FY25)
• Crushing Capacity: Doubled to 1,650 MT/day
• Recommended Dividend: ₹0.25 per share

Investor Watchlist

Key areas for investors to monitor include the successful commissioning of new facilities in FY27 for modified starch products and dextrose variants. The company's ability to improve operating margins, despite increased scale, and its progress in executing its strategy to become a diversified specialty products company will be critical for future valuation.